UCB, Biogen admit defeat in PhII lupus trial, adding to a string of late-stage failures in the field

A late-stage lupus program at UCB and Biogen has followed several rivals into a wall.

Without providing details, the partners reported that their drug, dapirolizumab pegol (DZP), had failed to meet the primary endpoint, as measured by dose response at 24 weeks on a scale called the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA).